$FBIO
Fortress Biotech, Inc. Stock $fbio

$fbio Overview Financials Valuation SEC Filings Company Website

2013 Q4 Form 10-Q Financial Statement

#000119312513423193 Filed on November 01, 2013

Income Statement

Concept	2013 Q4	2013 Q3	2012 Q3
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.970M	$2.140M	$2.050M
YoY Change	10.82%	4.39%	15.17%
% of Gross Profit
Research & Development	$6.550M	$5.361M	$3.777M
YoY Change	16.55%	41.94%	115.83%
% of Gross Profit
Depreciation & Amortization	$10.00K	$0.00	$0.00
YoY Change			-100.0%
% of Gross Profit
Operating Expenses	$9.520M	$5.361M	$3.777M
YoY Change	14.7%	41.94%	7.0%
Operating Profit	-$9.524M	-$7.504M	-$5.831M
YoY Change	14.76%	28.69%
Interest Expense	-$270.0K	$493.0K	$183.0K
YoY Change	-27.03%	169.4%	7.65%
% of Operating Profit
Other Income/Expense, Net			$0.00
YoY Change
Pretax Income	-$9.800M	-$7.830M	-$5.940M
YoY Change	13.16%	31.82%	76.26%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$9.798M	-$7.832M	-$5.935M
YoY Change	13.09%	31.96%	76.11%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$274.4K	-$240.0K	-$243.6K
COMMON SHARES
Basic Shares Outstanding	35.61M shares	31.90M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2013 Q4	2013 Q3	2012 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$99.50M	$106.3M	$47.50M
YoY Change	147.51%	123.79%	77.9%
Cash & Equivalents	$99.52M	$106.3M	$47.48M
Short-Term Investments
Other Short-Term Assets	$500.0K	$300.0K	$500.0K
YoY Change	25.0%	-40.0%	400.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$100.0M	$106.5M	$48.00M
YoY Change	146.43%	121.97%	79.1%
LONG-TERM ASSETS
Property, Plant & Equipment	$447.0K	$452.0K
YoY Change	776.47%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$104.0K	$109.0K	$100.0K
YoY Change	-70.2%	9.0%
Total Long-Term Assets	$551.0K	$561.0K	$100.0K
YoY Change	37.75%	461.0%
TOTAL ASSETS
Total Short-Term Assets	$100.0M	$106.5M	$48.00M
Total Long-Term Assets	$551.0K	$561.0K	$100.0K
Total Assets	$100.6M	$107.1M	$48.10M
YoY Change	145.37%	122.68%	79.48%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$468.0K	$1.114M	$800.0K
YoY Change	-54.52%	39.25%
Accrued Expenses	$4.430M	$2.352M	$3.600M
YoY Change	102.75%	-34.67%	125.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$6.200M	$6.100M	$0.00
YoY Change	244.44%
Total Short-Term Liabilities	$11.21M	$9.644M	$4.500M
YoY Change	118.43%	114.31%	21.62%
LONG-TERM LIABILITIES
Long-Term Debt	$7.000M	$8.400M	$14.10M
YoY Change	-43.55%	-40.43%	1662.5%
Other Long-Term Liabilities	$1.077M	$1.541M	$400.0K
YoY Change	-25.26%	285.25%
Total Long-Term Liabilities	$1.077M	$1.541M	$14.50M
YoY Change	-25.26%	-89.37%	1712.5%
TOTAL LIABILITIES
Total Short-Term Liabilities	$11.21M	$9.644M	$4.500M
Total Long-Term Liabilities	$1.077M	$1.541M	$14.50M
Total Liabilities	$19.30M	$19.59M	$19.00M
YoY Change	1.82%	3.12%	331.82%
SHAREHOLDERS EQUITY
Retained Earnings	-$121.3M	-$111.5M
YoY Change	44.14%
Common Stock	$40.00K	$35.00K
YoY Change	66.67%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$81.28M	$87.51M	$29.10M
YoY Change
Total Liabilities & Shareholders Equity	$100.6M	$107.1M	$48.10M
YoY Change	145.37%	122.68%	79.48%

Cashflow Statement

Concept	2013 Q4	2013 Q3	2012 Q3
OPERATING ACTIVITIES
Net Income	-$9.798M	-$7.832M	-$5.935M
YoY Change	13.09%	31.96%	76.11%
Depreciation, Depletion And Amortization	$10.00K	$0.00	$0.00
YoY Change			-100.0%
Cash From Operating Activities	-$7.140M	-$7.220M	-$4.660M
YoY Change	0.56%	54.94%	59.04%
INVESTING ACTIVITIES
Capital Expenditures	$150.0K	$80.00K	$0.00
YoY Change	-400.0%
Acquisitions
YoY Change
Other Investing Activities	-$150.0K
YoY Change	-34.78%
Cash From Investing Activities	$0.00	$80.00K	$0.00
YoY Change	-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	390.0K	45.52M	13.93M
YoY Change	290.0%	226.78%	-139400.0%
NET CHANGE
Cash From Operating Activities	-7.140M	-7.220M	-4.660M
Cash From Investing Activities	0.000	80.00K	0.000
Cash From Financing Activities	390.0K	45.52M	13.93M
Net Change In Cash	-6.750M	38.38M	9.270M
YoY Change	-7.28%	314.02%	-415.31%
FREE CASH FLOW
Cash From Operating Activities	-$7.140M	-$7.220M	-$4.660M
Capital Expenditures	$150.0K	$80.00K	$0.00
Free Cash Flow	-$7.290M	-$7.300M	-$4.660M
YoY Change	3.4%	56.65%	59.04%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2013Q1	cndo	Percentage Of Right In Joint Intellectual Property PercentageOfRightInJointIntellectualProperty	0.10	pure
CY2013Q3	cndo	Capital Stock Shares Authorized CapitalStockSharesAuthorized	65000000	shares
CY2013Q3	cndo	Maximum Sale Of Common Stock Authorized Shares Under Agreement MaximumSaleOfCommonStockAuthorizedSharesUnderAgreement	200000000
CY2013Q2	us-gaap	Share Price SharePrice	4.56
CY2012Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	47478000
CY2012Q3	cndo	Maximum Sale Of Common Stock Authorized Shares Under Agreement MaximumSaleOfCommonStockAuthorizedSharesUnderAgreement	75000000
CY2013Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	35255680	shares
CY2013Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	340	shares
CY2013Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	35255680	shares
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.87
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4130503	shares
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	4.87
CY2013Q3	us-gaap	Share Price SharePrice	7.01
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	3.95
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	4130503	shares
CY2013Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2013Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	1080899	shares
CY2013Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights	5.02
CY2013Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2352000
CY2013Q3	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	582000
CY2013Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	14000
CY2013Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	112000
CY2013Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	199023000
CY2013Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1114000
CY2013Q3	us-gaap	Notes Payable Current NotesPayableCurrent	6062000
CY2013Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	399000
CY2013Q3	us-gaap	Liabilities Current LiabilitiesCurrent	9644000
CY2013Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1541000
CY2013Q3	us-gaap	Stockholders Equity StockholdersEquity	87514000
CY2013Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-111544000
CY2013Q3	us-gaap	Accrual For Taxes Other Than Income Taxes Current AccrualForTaxesOtherThanIncomeTaxesCurrent	56000
CY2013Q3	us-gaap	Common Stock Value CommonStockValue	35000
CY2013Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	107107000
CY2013Q3	us-gaap	Long Term Notes Payable LongTermNotesPayable	8408000
CY2013Q3	us-gaap	Liabilities Liabilities	19593000
CY2013Q3	us-gaap	Interest Payable Current InterestPayableCurrent	116000
CY2013Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2013Q3	us-gaap	Assets Current AssetsCurrent	106546000
CY2013Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	109000
CY2013Q3	us-gaap	Assets Assets	107107000
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	8830000
CY2013Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	106267000
CY2013Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	466000
CY2013Q3	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	48000
CY2013Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	279000
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	8830000
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	4269000
CY2013Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	9100000
CY2013Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	452000
CY2013Q3	cndo	Number Of Equity Compensation Plan NumberOfEquityCompensationPlan	3	Plans
CY2013Q3	cndo	Other Long Term Liabilities Related To Manufacturing Rights OtherLongTermLiabilitiesRelatedToManufacturingRights	1143000
CY2013Q3	cndo	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	851000
CY2013Q3	cndo	Accrued Severance Cost AccruedSeveranceCost	352000
CY2013Q3	cndo	Notes Term Charges Payable NotesTermChargesPayable	398000
CY2013Q3	cndo	Other Long Term Liabilities OtherLongTermLiabilities	1541000
CY2013Q3	cndo	Capital Stock Shares Authorized CapitalStockSharesAuthorized	115000000	shares
CY2013Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	35611883	shares
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	23160000
CY2012Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	24400754	shares
CY2012Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	24400754	shares
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.37
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2519070	shares
CY2012Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2012Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2012Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2185000
CY2012Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	320000
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5132000
CY2012Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1441000
CY2012Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	1064000
CY2012Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3000
CY2012Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	44000
CY2012Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	106193000
CY2012Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1029000
CY2012Q4	us-gaap	Notes Payable Current NotesPayableCurrent	1799000
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	22033000
CY2012Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-84184000
CY2012Q4	us-gaap	Common Stock Value CommonStockValue	24000
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	40992000
CY2012Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	12386000
CY2012Q4	us-gaap	Liabilities Liabilities	18959000
CY2012Q4	us-gaap	Interest Payable Current InterestPayableCurrent	119000
CY2012Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2012Q4	us-gaap	Assets Current AssetsCurrent	40592000
CY2012Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	349000
CY2012Q4	us-gaap	Assets Assets	40992000
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	40199000
CY2012Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	54000
CY2012Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	393000
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	2860000
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	51000
CY2012Q4	cndo	Other Long Term Liabilities Related To Manufacturing Rights OtherLongTermLiabilitiesRelatedToManufacturingRights	1043000
CY2012Q4	cndo	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	403000
CY2012Q4	cndo	Accrued Severance Cost AccruedSeveranceCost	354000
CY2012Q4	cndo	Notes Term Charges Payable NotesTermChargesPayable	398000
CY2012Q4	cndo	Other Long Term Liabilities OtherLongTermLiabilities	1441000
CY2013Q1	cndo	Joint Ownership And Exclusive License Agreement Termination Written Notice Period JointOwnershipAndExclusiveLicenseAgreementTerminationWrittenNoticePeriod	P180D
CY2013Q1	cndo	Joint Ownership And Exclusive License Agreement Termination Notice Period JointOwnershipAndExclusiveLicenseAgreementTerminationNoticePeriod	P60D
CY2013Q1	cndo	Period Of Notice To Cure Termination Due To Breach PeriodOfNoticeToCureTerminationDueToBreach	P60D
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-69606000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	339000
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-117405000
	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	80000
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	733000
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	737000
	us-gaap	Investment Income Interest InvestmentIncomeInterest	830000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-106293000
	us-gaap	Interest Paid InterestPaid	1609000
	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	3843000
	us-gaap	Net Income Loss NetIncomeLoss	-111544000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	507000
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	3466000
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	121000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	23405000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	180223000
	us-gaap	Increase Decrease In Notes Payable Related Parties IncreaseDecreaseInNotesPayableRelatedParties	-600000
	us-gaap	Dividends Common Stock Stock DividendsCommonStockStock	5861000
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	106267000
	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	11584000
	us-gaap	Interest Expense InterestExpense	5407000
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	119682000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4350000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	61139000
	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	80000
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	21749000
	us-gaap	Depreciation Depreciation	55000
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	116000
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	7570000
	cndo	Contribution Of Services By Stockholder ContributionOfServicesByStockholder	130000
	cndo	Noncash Interest NoncashInterest	2298000
	cndo	Change In Preferred Stock Warrant Liability ChangeInPreferredStockWarrantLiability	-1407000
	cndo	Change In Fair Value Of Embedded Conversion Feature ChangeInFairValueOfEmbeddedConversionFeature	831000
	cndo	Change In Fair Value Of Common Stock Warrant Liability ChangeInFairValueOfCommonStockWarrantLiability	-234000
	cndo	Payment Of Costs Related To Issuance Of Common Stock PaymentOfCostsRelatedToIssuanceOfCommonStock	4165000
	cndo	Payment Of Notes Payable Asset Purchase Agreement PaymentOfNotesPayableAssetPurchaseAgreement	750000
	cndo	Proceeds From Notes Payable To Related Parties ProceedsFromNotesPayableToRelatedParties	2221000
	cndo	Warrant Expense WarrantExpense	1407000
	cndo	Payment For Notes Payable Related Party PaymentForNotesPayableRelatedParty	570000
	cndo	Noncash Interest Related Parties NoncashInterestRelatedParties	286000
	cndo	Assumed Note Related To Asset Purchase AssumedNoteRelatedToAssetPurchase	750000
	cndo	Proceeds From Notes Payable Related Parties ProceedsFromNotesPayableRelatedParties	570000
	dei	Entity Registrant Name EntityRegistrantName	CORONADO BIOSCIENCES INC
	dei	Amendment Flag AmendmentFlag	false
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2013
	dei	Document Type DocumentType	10-Q
	dei	Document Period End Date DocumentPeriodEndDate	2013-09-30
	dei	Entity Central Index Key EntityCentralIndexKey	0001429260
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P7Y8M12D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y7M6D
	us-gaap	Stock Issued During Period Shares Issued For Noncash Consideration StockIssuedDuringPeriodSharesIssuedForNoncashConsideration	80705	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	28664822	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	6.07
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-22514000
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.95
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.70
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2031590	shares
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y6M
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y7M6D
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	400157	shares
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div> <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 4%; FONT-SIZE: 10pt"> <b>Concentration of Risk</b></p> <p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 4%; FONT-SIZE: 10pt"> The Company is currently completely dependent on third party manufacturers for product supply. In particular, the Company relies exclusively on Ovamed GmbH (“Ovamed”) to supply it with its requirements of <i>Trichuris suis</i> ova (“TSO”). Ovamed is the sole supplier of this product, which it is currently producing at only one facility in Germany, where it is also producing product for others, including Dr. Falk Pharma GmbH (“Falk”). Ovamed also relies on certain other suppliers for materials and services. Also, the Company currently relies on BioReliance Corporation, Progenitor Cell Therapy LLC and other third parties for its CNDO–109 product requirements. The Company’s clinical development programs would be adversely affected by a significant interruption in obtaining clinical trial supplies.</p> </div>
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5228805	shares
	us-gaap	Use Of Estimates UseOfEstimates	<div> <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 4%; FONT-SIZE: 10pt"> <b>Use of Estimates</b></p> <p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 4%; FONT-SIZE: 10pt"> The Company’s consolidated financial statements include certain amounts that are based on management’s best estimates and judgments. The Company’s significant estimates include, but are not limited to, useful lives assigned to long-lived assets, compensation expenses related to Common Stock, warrants and options, accrued expenses, provisions for income taxes and contingencies. Due to the uncertainty inherent in such estimates, actual results may differ from our estimates.</p> </div>
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-114000
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-27360000
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	680000
	us-gaap	Investment Income Interest InvestmentIncomeInterest	350000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-26256000
	us-gaap	Interest Paid InterestPaid	1052000
	us-gaap	Net Income Loss NetIncomeLoss	-27360000
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	83000
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4072000
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	88006000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	187000
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	252000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7126000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	88769000
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1098
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	66068000
	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	4072000
	us-gaap	Interest Expense InterestExpense	1454000
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	90629000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-187000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	19130000
	us-gaap	Depreciation Depreciation	11000
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-3000
	cndo	Noncash Interest NoncashInterest	400000
	cndo	Number Of Warrants Exercised NumberOfWarrantsExercised	158429	shares
	cndo	Payment Of Costs Related To Issuance Of Common Stock PaymentOfCostsRelatedToIssuanceOfCommonStock	1860000
	cndo	Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod	20000	shares
	cndo	Payment Of Costs Related To Issuance Of Common Stock PaymentOfCostsRelatedToIssuanceOfCommonStock	2305000
	cndo	Payment Of Notes Payable Asset Purchase Agreement PaymentOfNotesPayableAssetPurchaseAgreement	750000
	cndo	Share Based Compensation Arrangements By Share Based Payment Award Options Cancelled In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice	1.93
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	20738007	shares
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16089000
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.91
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3298612	shares
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	324000
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-18945000
	us-gaap	Investment Income Interest InvestmentIncomeInterest	152000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-18877000
	us-gaap	Interest Paid InterestPaid	36000
	us-gaap	Net Income Loss NetIncomeLoss	-18945000
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	875000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5984000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	40407000
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	24318000
	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	2173000
	us-gaap	Interest Expense InterestExpense	220000
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	28750000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12893000
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	97000
	cndo	Noncash Interest NoncashInterest	35000
CY2013Q2	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	21505	shares
CY2013Q2	cndo	Percentage Of Closing Price For Purchase Price Of Common Stock Under Employee Stock Purchase Plan PercentageOfClosingPriceForPurchasePriceOfCommonStockUnderEmployeeStockPurchasePlan	0.85	pure
CY2013Q2	cndo	Shares Issued Under Employee Stock Purchase Plan Average Price Per Share SharesIssuedUnderEmployeeStockPurchasePlanAveragePricePerShare	3.88
CY2012	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y6M
CY2012Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	24375749	shares
CY2012Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.24
CY2012Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3459636	shares
CY2012Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5935000
CY2012Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	79000
CY2012Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-5831000
CY2012Q3	us-gaap	Net Income Loss NetIncomeLoss	-5935000
CY2012Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2054000
CY2012Q3	us-gaap	Interest Expense InterestExpense	183000
CY2012Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3777000
CY2013Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	32634683	shares
CY2013Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.24
CY2013Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5326424	shares
CY2013Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-7832000
CY2013Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	165000
CY2013Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-7504000
CY2013Q3	us-gaap	Net Income Loss NetIncomeLoss	-7832000
CY2013Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2143000
CY2013Q3	us-gaap	Interest Expense InterestExpense	493000
CY2013Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5361000

Files In Submission

Name	View Source	Status
0001193125-13-423193-index-headers.html	Edgar Link	pending
0001193125-13-423193-index.html	Edgar Link	pending
0001193125-13-423193.txt	Edgar Link	pending
0001193125-13-423193-xbrl.zip	Edgar Link	pending
cndo-20130930.xml	Edgar Link	completed
cndo-20130930.xsd	Edgar Link	pending
cndo-20130930_cal.xml	Edgar Link	unprocessable
cndo-20130930_def.xml	Edgar Link	unprocessable
cndo-20130930_lab.xml	Edgar Link	unprocessable
cndo-20130930_pre.xml	Edgar Link	unprocessable
d594046d10q.htm	Edgar Link	pending
d594046dex311.htm	Edgar Link	pending
d594046dex312.htm	Edgar Link	pending
d594046dex321.htm	Edgar Link	pending
d594046dex322.htm	Edgar Link	pending
d594046dex35.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$FBIO
Fortress Biotech, Inc. Stock $fbio

2013 Q4 Form 10-Q Financial Statement

#000119312513423193 Filed on November 01, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FBIO Fortress Biotech, Inc. Stock $fbio

2013 Q4 Form 10-Q Financial Statement

#000119312513423193 Filed on November 01, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FBIO
Fortress Biotech, Inc. Stock $fbio